Search

Displaying results 9521 - 9530 of 10000 in total
  1. Drug

    NV1020

    go.drugbank.com/drugs/DB04969
    Investigational

    NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

  2. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity.

  3. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  4. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver. … MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer.

  5. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.

    Categories: Adenosine A receptor agonists
  6. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET).

  7. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.

  8. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  9. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer.

  10. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    EP3 is a target that associates with increased risk of various vascular diseases. … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2.